Investment firm Oberland Capital said today that it has closed its second royalty and credit opportunities fund, Oberland Capital Healthcare II LP (Fund II), at its hard cap of $800 million in capital commitments. The fund will target investments between $20 million and $150 million with a focus on commercial stage or near-commercial stage biopharmaceutical, […]
Here are the pharma companies accused of blocking generic competition
To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]
Sunrise Labs executes succession plan | Personnel Moves – April 5, 2018
Medical device and life science development group Sunrise Labs said this week that it completed its succession plan, with president Eric Soederberg acquiring the majority of shares in the company through a stock sale with founder and board chair Drew Sunstein. With the transaction, the Bedford, N.H.-based company said that it secured its planned ownership […]
Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies
The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the groups plan to commit $12 million to […]
Novocure brings Optune tech to drug trial for glioblastoma
Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Get the full story at our […]
Leukemia trial to match patients with drugs based on genetic biomarkers
The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational AML treatments. The non-profit […]
Celgene acquires Delinia, beats on Q4 earnings
Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth […]
Evotec, Celgene ink drug development deal for stem cell treatments for neurodegenerative diseases
Evotec (ETR:EVT) said today that it inked a 5-year drug discovery and development deal with Celgene (NSDQ:CELG) to identify stem cell therapies for a range of neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. According to the agreement, Hamburg, Germany-based Evotec will receive an upfront payment of $45 million and Celgene will hold exclusive […]
Celgene invests in GNS
Celgene (NSDQ:CELG) said this week that it has made another investment in GNS Healthcare and inked a deal with the bioanalytics firm for its “Reverse Engineering and Forward Simulation” software. GNS’s software analyzes health data, including electronic health records, pharmacy claims and genomic sequences, and uses machine learning to answer questions in healthcare. The multi-year agreement […]
Misonix CEO steps down | Personnel Moves October 4, 2016
Misonix CEO steps down Misonix (NSDQ:MSON) CEO Michael McManus, Jr. stepped down in early September, also leaving his post as director and chairman of the board of directors. Stavros Vizirgianakis, a member of the board of directors, is serving as the interim CEO while negotiating for a full-time position in the corner office. Vizirgiankis, who owned […]
Celgene inks collab deal with EMR firm Trinetx
Celgene (NSDQ:CELG) said today it inked a collaborative deal with TriNetX to develop advanced clinical trial design for Celgene’s next-gen therapeutic programs. Through the deal, Celgene will be able to access medical data from electronic medical records through TriNetX’s proprietary network of healthcare institutions, the companies said. “TriNetX represents the future of a data-driven approach to […]
